{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:05:41Z","timestamp":1783098341981,"version":"3.54.6"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Bullous systemic lupus erythematosus (BSLE) is a rare blistering presentation of systemic lupus erythematosus, typically affecting women with the highest incidence in those of African descent. The key pathogenic insult includes the formation of autoantibodies against type VII collagen, which weaken the basement membrane zone and lead to the formation of subepidermal blisters. The acute vesiculobullous eruptions in BSLE generally tend to affect photo-distributed areas, although they can arise unrelated to sun exposure (eg, mucous membranes, axillae). The bullae can arise from erythematous macules, inflammatory plaques, or previously normal skin. Their appearance can range from small, grouped vesicles reminiscent of lesions in dermatitis herpetiformis to large, tense blisters, similar to bullous pemphigoid. Internal organ involvement occurs in up to 90% of those affected. This mostly includes lupus nephritis (classes III\u2013V, lifetime prevalence of up to 90%), arthralgias\/arthritis, and cytopenias, while serositis and neuropsychiatric involvement are rare. First-line management with dapsone should be considered in mild disease with stable underlying systemic lupus erythematosus. As discussed in this review, the off-label use of rituximab (an anti-CD20 B-cell depleting agent) has been shown to be safe and effective in several refractory cases of BSLE unresponsive to dapsone, glucocorticoids, or steroid-sparing immunosuppressants.<\/jats:p>","DOI":"10.1097\/jw9.0000000000000034","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T17:05:35Z","timestamp":1659373535000},"page":"e034","source":"Crossref","is-referenced-by-count":20,"title":["Bullous systemic lupus erythematosus in females"],"prefix":"10.1097","volume":"8","author":[{"given":"Grant","family":"Sprow","sequence":"first","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania"},{"name":"Corporal Michael J. Crescenz Veterans Affairs Medical Center, Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Afarideh","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania"},{"name":"Corporal Michael J. Crescenz Veterans Affairs Medical Center, Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Dan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania"},{"name":"Corporal Michael J. Crescenz Veterans Affairs Medical Center, Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Hedberg","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria P.","family":"Werth","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania"},{"name":"Corporal Michael J. Crescenz Veterans Affairs Medical Center, Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,7,27]]},"reference":[{"issue":"2","key":"R1-20231102","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.clindermatol.2003.12.020","article-title":"Bullous systemic lupus erythematosus.","volume":"22","author":"Vassileva","year":"2004","journal-title":"Clin Dermatol"},{"issue":"4","key":"R2-20231102","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.det.2011.06.002","article-title":"Bullous systemic lupus erythematosus.","volume":"29","author":"Sebaratnam","year":"2011","journal-title":"Dermatol Clin"},{"issue":"12","key":"R3-20231102","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1177\/0961203317699714","article-title":"A 12-year retrospective review of bullous systemic lupus erythematosus in cutaneous and systemic lupus erythematosus patients.","volume":"26","author":"Chanprapaph","year":"2017","journal-title":"Lupus"},{"issue":"10","key":"R4-20231102","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1177\/0961203318776104","article-title":"A 12-year retrospective review of bullous systemic lupus erythematosus in cutaneous and systemic lupus erythematosus patients.","volume":"27","author":"Pons-Estel","year":"2018","journal-title":"Lupus"},{"issue":"12","key":"R5-20231102","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/j.1346-8138.2005.tb00894.x","article-title":"Bullous systemic lupus erythematosus as an initial manifestation of SLE.","volume":"32","author":"Fujimoto","year":"2005","journal-title":"J Dermatol"},{"issue":"2","key":"R6-20231102","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1600-0560.1993.tb00225.x","article-title":"Hermann Pinkus Memorial Lecture\u20131992. Autoimmunity to collagen VII: autoantibody-mediated pathomechanisms regulate clinical-pathological phenotypes of acquired epidermolysis bullosa and bullous SLE.","volume":"20","author":"Gammon","year":"1993","journal-title":"J Cutan Pathol"},{"issue":"5","key":"R7-20231102","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/archderm.135.5.569","article-title":"Bullous systemic lupus erythematosus with autoantibodies recognizing multiple skin basement membrane components, bullous pemphigoid antigen 1, laminin-5, laminin-6, and type VII collagen.","volume":"135","author":"Chan","year":"1999","journal-title":"Arch Dermatol"},{"issue":"6","key":"R8-20231102","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0190-9622(83)70210-0","article-title":"Vesiculobullous systemic lupus erythematosus. Report of two cases and a review of the literature.","volume":"9","author":"Camisa","year":"1983","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"R9-20231102","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/1523-1747.ep12355583","article-title":"Indirect immunofluorescence in vesiculobullous eruption of systemic lupus erythematosus.","volume":"86","author":"Camisa","year":"1986","journal-title":"J Invest Dermatol"},{"issue":"3","key":"R10-20231102","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.jaad.2011.12.032","article-title":"Sensitive and specific assays for routine serological diagnosis of epidermolysis bullosa acquisita.","volume":"68","author":"Komorowski","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"R11-20231102","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.semarthrit.2017.11.003","article-title":"Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 new cases and a literature review of 118 cases.","volume":"48","author":"de Risi-Pugliese","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"R12-20231102","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1191\/0961203303lu241cr","article-title":"Bullous SLE: response to methotrexate and relationship with disease activity.","volume":"12","author":"Malcangi","year":"2003","journal-title":"Lupus"},{"key":"R13-20231102","first-page":"17","article-title":"Bullous systemic lupus erythematosus with lupus nephritis: a rare case of a subepidermal bullous disorder in a child.","volume":"89","author":"Poojary","year":"2012","journal-title":"Cutis"},{"issue":"2","key":"R14-20231102","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.lpm.2017.11.021","article-title":"Bullous systemic lupus erythematosus.","volume":"47","author":"Elqatni","year":"2018","journal-title":"Presse Med"},{"issue":"6","key":"R15-20231102","doi-asserted-by":"crossref","first-page":"453","DOI":"10.5001\/omj.2016.91","article-title":"Bullous systemic lupus erythematosus and lupus nephritis in a young girl.","volume":"31","author":"Momen","year":"2016","journal-title":"Oman Med J"},{"issue":"11","key":"R16-20231102","first-page":"861","article-title":"Bullous systemic lupus erythematosus and lupus nephritis in a 10 year old boy.","volume":"44","author":"Vijayalakshmi","year":"2007","journal-title":"Indian Pediatr"},{"issue":"4","key":"R17-20231102","doi-asserted-by":"crossref","first-page":"431","DOI":"10.5114\/ada.2018.77676","article-title":"Bullous systemic lupus erythematosus associated with increased activity of lupus nephritis: a case report and review of the literature.","volume":"35","author":"\u017bychowska","year":"2018","journal-title":"Postepy Dermatol Alergol"},{"key":"R18-20231102","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/j.jaad.2013.01.025","article-title":"IgG autoantibody subclass analysis as a tool to differentiate epidermolysis bullosa acquisita with overlapping features of bullous systemic lupus erythematosus.","volume":"69","author":"Gual","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"R19-20231102","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jaut.2009.11.003","article-title":"Pathogenicity of IgG subclass autoantibodies to type VII collagen: induction of dermal-epidermal separation.","volume":"34","author":"Recke","year":"2010","journal-title":"J Autoimmun"},{"issue":"5 Pt 2","key":"R20-20231102","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S0190-9622(98)70472-4","article-title":"Bullous systemic lupus erythematosus: detection of antibodies against noncollagenous domain of type VII collagen.","volume":"38","author":"Shirahama","year":"1998","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"R21-20231102","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1191\/0961203304lu2037sa","article-title":"Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): a case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions.","volume":"13","author":"Ting","year":"2004","journal-title":"Lupus"},{"issue":"3","key":"R22-20231102","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/RHU.0b013e318214f30c","article-title":"Rituximab in the treatment of bullous systemic lupus erythematosus.","volume":"17","author":"Alsanafi","year":"2011","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"R23-20231102","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-97-2-165","article-title":"Bullous eruption of systemic lupus erythematosus: dramatic response to dapsone therapy.","volume":"97","author":"Hall","year":"1982","journal-title":"Ann Intern Med"},{"issue":"10083","key":"R25-20231102","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"R26-20231102","doi-asserted-by":"crossref","first-page":"167064","DOI":"10.1155\/2015\/167064","article-title":"Treatment of bullous systemic lupus erythematosus.","volume":"2015","author":"Duan","year":"2015","journal-title":"J Immunol Res"},{"issue":"10 Suppl 8","key":"R27-20231102","first-page":"63","article-title":"Newer treatments for non-Hodgkin\u2019s lymphoma: monoclonal antibodies.","volume":"12","author":"Maloney","year":"1998","journal-title":"Oncology (Williston Park)"},{"issue":"3","key":"R28-20231102","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1365-2141.2009.07718.x","article-title":"Rituximab in non-haematological disorders of adults and its mode of action.","volume":"146","author":"McDonald","year":"2009","journal-title":"Br J Haematol"},{"key":"R29-20231102","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40257-019-00497-9","article-title":"Rituximab: a review in pemphigus vulgaris.","volume":"21","author":"Frampton","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"R30-20231102","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1002\/acr.24332","article-title":"Long-term safety of rituximab in granulomatosis with polyangiitis and in microscopic polyangiitis.","volume":"73","author":"Merkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"R31-20231102","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/0961203309106174","article-title":"Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases.","volume":"18","author":"Ramos-Casals","year":"2009","journal-title":"Lupus"},{"issue":"10","key":"R32-20231102","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1365-4632.2006.03007.x","article-title":"Rituximab: applications in dermatology.","volume":"45","author":"Fatourechi","year":"2006","journal-title":"Int J Dermatol"},{"issue":"8","key":"R33-20231102","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(21)00167-8","article-title":"Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions.","volume":"8","author":"Bennett","year":"2021","journal-title":"Lancet Haematol"},{"key":"R34-20231102","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3324\/haematol.10564","article-title":"Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen.","volume":"92","author":"Kolstad","year":"2007","journal-title":"Haematologica"},{"issue":"10","key":"R35-20231102","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/art.38051","article-title":"Oral mucosal involvement in bullous lupus.","volume":"65","author":"Anyanwu","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"6","key":"R36-20231102","first-page":"E5","article-title":"Bullous systemic lupus erythematosus successfully treated with rituximab.","volume":"103","author":"Lowe","year":"2019","journal-title":"Cutis"}],"container-title":["International Journal of Women\u2019s Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JW9.0000000000000034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T18:25:15Z","timestamp":1698949515000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JW9.0000000000000034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,27]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/jw9.0000000000000034","relation":{},"ISSN":["2352-6475"],"issn-type":[{"value":"2352-6475","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,27]]}}}